Published in Open Forum Infect Dis on September 16, 2014
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol (2015) 0.79
No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy. BBA Clin (2015) 0.78
Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. Viral Immunol (2016) 0.75
Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China. Medicine (Baltimore) (2017) 0.75
Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS One (2016) 0.75
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res (2016) 0.75
The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors. PLoS One (2016) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology (2015) 6.73
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques (1993) 2.65
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis (2013) 1.61
Treating hepatitis C in lower-income countries. N Engl J Med (2014) 1.52
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol (2012) 1.50
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol (2012) 1.35
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother (2012) 1.21
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther (2011) 1.16
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol (2012) 1.16
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol (2013) 0.91
Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b. Methods Mol Biol (2013) 0.84
Clinical relevance of HCV antiviral drug resistance. Curr Opin Virol (2012) 0.84
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Curr Gastroenterol Rep (2012) 0.81
Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol (2013) 0.80